$AKTX News

Akari Targets Mid-2027 for Human Trial of Differentiated Cancer Therapy

Akari Therapeutics Announces Preclinical Data Of AKTX-101 Shows Anti-Tumor Activity Throughout Multiple Clinically Relevant Urothelial Cancer Preclinical Models

Akari Therapeutics Says Strategic Research Collaboration With Whitehawk Therapeutics Expands Potential Application Of Akari’s PH1 Platform Into Dual-Payload ADCs

Akari Therapeutics Announces Strategic Research Collaboration With Whitehawk To Conduct Preclinical Studies Evaluating PH1 Spliceosome-Modulating Payload Technology In Combination With TOP1i ADC Platform

Maxim Group Upgrades Akari Therapeutics to Buy, Announces $30 Price Target

Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board

Akari Therapeutics Files Prospectus Related To Resale Of Up To 6M ADSs Representing 480B Ordinary Shares By The Selling Shareholders

Akari Therapeutics Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory Milestones

Akari Therapeutics Releases CEO Corner Reflecting on Evolving ADC Landscape and Akari’s Differentiated PH1 Payload Platform Following ASCO 2026

Akari Therapeutics Discusses Breakthrough Potential of AKTX-101 and Novel Spliceosome-Modulating ADC Platform in Virtual Investor “What This Means” Segment Following ASCO Abstract Acceptance

Akari Therapeutics CEO Highlights ASCO Data Demonstrating Synergy Of AKTX-101 With Adagasrib In KRAS-Driven Cancers In Virtual Investor "What This Means" Segment

Why Akari Therapeutics Stock Is Falling On Tuesday?

Akari Therapeutics Stock Jumps On Promising Preclinical Data

Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models

Akari Therapeutics' AKTX-101 Shows Synergistic Preclinical Cytotoxicity With KRAS Inhibitor In KRAS-Mutant Pancreatic Cancer Models, Highlighting RNA Splicing Payload Advantage

Akari Therapeutics Announces $5.5 Million Private Placement Offering

Akari Therapeutics Commences $5.5M Private Placement

Akari Therapeutics to Present at A.G.P.’s Annual Healthcare Company Showcase

Why Akari Therapeutics Stock Is Surging On Thursday?

Akari Therapeutics Granted European Patent For Proprietary ADC Payload Platform Technology